Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2051250123) titled 'Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC' on Oct. 1.
Study Type: Interventional
Study Design:
non-randomized controlled trial, open(masking not used), uncontrolled control, parallel assignment, treatment purpose
Primary Sponsor: Hibi Kazushige
Condition:
locally advanced or metastatic NSCLC
Intervention:
Sub-study 1, investigate rilvegostomig+- ramucirumab in 1L non-AGA NSCLC with PD-L1 50% or more
Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%
Su...